TITLE:
Impact of Switch to Fosamprenavir and Addition of Lovaza® for Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy
AUTHORS:
Franco Felizarta, Anthony Scarsella, Homayoon Khanlou, Winston Young, Lisa Ross, Henry Zhao, Keith Pappa, Belinda Ha
KEYWORDS:
Fish Oil; Fosamprenavir; HIV; Hypertriglyceridemia; Lovaza; Switch; Triglycerides
JOURNAL NAME:
World Journal of AIDS,
Vol.2 No.1,
March
22,
2012
ABSTRACT: Background: Managing hypertriglyceridemia in HIV-infected patients often requires multiple pharmacologic strategies. Many protease inhibitors (PIs), one of 6 classes of drugs used to treat HIV, have been associated with hypercholesterolemia and drug interactions. For this study, we examined a dual strategy to manage hypertriglyceridemia in HIV-infected patient taking PIs: 1) switching patients to fosamprenavir (FPV), a PI with fewer drug interactions, and 2) adding prescription fish oil (LOVAZA?), which has been shown to reduce triglycerides. Methods: This multicenter, 24-week study enrolled 36 patients virologically suppressed (HIV-1 RNA